Aperture Therapeutics Inc. has advanced its matrix metalloproteinase-9 (MMP-9) antisense oligonucleotide (ASO) program, APRTX-003, for the treatment of amyotrophic lateral sclerosis (ALS). This first-in-class RNA-targeting approach program targets chronic neuroinflammation and neurodegeneration.